NCT02795858 2025-02-19A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid TumorsDana-Farber Cancer InstitutePhase 2 Completed43 enrolled 11 charts